Research and development

Pet Honesty® Introduces Groundbreaking Restore + Soothe Line, Elevating Pet Skincare with MicroSilver BG™ Innovation

Retrieved on: 
Wednesday, February 21, 2024

Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.

Key Points: 
  • Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.
  • At the core of the Restore + Soothe line is MicroSilver BG™, a clinically studied ingredient crafted from pure, elemental silver.
  • Greg Reinhart, Ph.D, Vice President of Research & Development at Pet Honesty, expressed enthusiasm for MicroSilver BG™, stating, “MicroSilver BG™ is a game-changer in pet skincare.
  • The Restore + Soothe Spray ($14.99) offers fast relief in a natural formulation, and the Restore + Soothe Ear Cleaner ($19.99) provides quick relief for ear issues.

Mercedes-Benz Group 2023 Results*: Cash Generation at Work

Retrieved on: 
Thursday, February 22, 2024

Any future free cash flow from the industrial business as available (post potential small-scale M&A) beyond the approx.

Key Points: 
  • Any future free cash flow from the industrial business as available (post potential small-scale M&A) beyond the approx.
  • 40 percent dividend payout ratio of Group Net Income, shall be used to fund share buybacks with the purpose of redeeming shares.
  • Group Free Cash Flow of the Industrial Business is seen slightly below the very strong levels from 2023, due to lower EBIT at Cars and Vans and lower CCR at Vans.
  • Link to capital market presentation on full year 2023: group.mercedes-benz.com/results-2023
    Pictures of the Annual Results Conference 2023 will be available here: group-media.mercedes-benz.com
    Further information on Mercedes-Benz Group AG is available at:

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Retrieved on: 
Wednesday, February 21, 2024

Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.

Key Points: 
  • Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.
  • The companies also plan to initiate a Phase 2 trial to evaluate domvanalimab plus zimberelimab in a new disease setting.
  • Arcus will host a conference call and webcast today, February 21, at 2:00 PM PT / 5:00 PM ET to discuss its fourth-quarter and full-year 2023 financial results and pipeline updates.
  • To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com .

Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business

Retrieved on: 
Monday, February 19, 2024

Net Sales of €895 MM represented year-on-year growth of 4%, driven by strong performance of the European Dermatology business.

Key Points: 
  • Net Sales of €895 MM represented year-on-year growth of 4%, driven by strong performance of the European Dermatology business.
  • Powered by our dedicated investments in launches and innovation, we achieved a 4% year-on-year growth in Net Sales, accounting for €895 MM, which was mainly driven by our European dermatology business.
  • Almirall has complemented its exciting pipeline and discovery efforts through strategic partnerships, adding long-term value to its medical dermatology portfolio.
  • The strategic focus on medical dermatology has positioned the company well for sustained growth and leadership in the medium term and beyond.

AbCellera Reports Full Year 2023 Business Results

Retrieved on: 
Tuesday, February 20, 2024

AbCellera started discovery on an additional twelve partner-initiated programs with downstreams to reach a cumulative total of 87 partner-initiated program starts with downstreams in 2023 (up from 75 on December 31, 2022).

Key Points: 
  • AbCellera started discovery on an additional twelve partner-initiated programs with downstreams to reach a cumulative total of 87 partner-initiated program starts with downstreams in 2023 (up from 75 on December 31, 2022).
  • The partnership business generated research fees of $35.6 million, compared to $40.8 million in 2022.
  • Revenue for the fourth quarter of 2023 was $9.2 million, representing 24% of total revenue for 2023.
  • AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

Steamroller Taps Shawn Dunn For Chief Technology Officer

Retrieved on: 
Friday, March 8, 2024

MOUNT DORA, Fla. , March 8, 2024 /PRNewswire-PRWeb/ -- Prior to joining Steamroller, Dunn was a Senior Product Manager at Epic Games where he was instrumental in the company's development direction of Unreal Engine in order for it to be easily adopted and used in the Media & Entertainment industry in Virtual Production, Visual Effects and Feature Animation. Shawn spent 3.5 years at Original Force, a privately owned animation studio with bases in Los Angeles, Beijing, Nanjing, Shanghai and Chengdu, where he was responsible for overseeing the technology foundation of the company, implementing IT and workflow innovations that support the creative and artistic process. Dunn also spent 13 years at Weta FX where he served as Head of Research and Development for the motion group, managing R&D for its animation, motion editing, pre-vis and crowd simulation units. Throughout his 28 year career, Shawn worked on over 30 feature films including Steven Spielberg's The Adventures of Tintin and The BFG, James Cameron's Avatar, Peter Jackson's Hobbit trilogy, King Kong, The Lord Of The Rings: The Return of the King, Rise of The Planet of The Apes, Iron Man 3, Man Of Steel, Dawn of the Planets of the Apes, The Avengers, X-Men: First Class and The Jungle Book.

Key Points: 
  • Steamroller Animation has announced that Shawn Dunn will be joining the studio as Chief Technology Officer.
  • Aaron Gilman, Chief Executive Officer of Steamroller Studios says, "We are beyond excited to welcome Shawn to Steamroller.
  • I have also been pushing real time workflows for most of my career and these are both areas that Steamroller Animation has been striving towards," says Shawn Dunn, Chief Technology Officer of Steamroller Studios.
  • Aaron Gilman, Chief Executive Officer of Steamroller Studios says, "We are beyond excited to welcome Shawn to Steamroller.

Eve Holding, Inc. Reports Fourth Quarter and FY2023 Results

Retrieved on: 
Friday, March 8, 2024

MELBOURNE, Fla., March 8, 2024 /PRNewswire/ -- Eve Holding, Inc. ("Eve") (NYSE: EVEX and EVEXW) reports its fourth quarter and fiscal year 2023 earnings results.

Key Points: 
  • MELBOURNE, Fla., March 8, 2024 /PRNewswire/ -- Eve Holding, Inc. ("Eve") (NYSE: EVEX and EVEXW) reports its fourth quarter and fiscal year 2023 earnings results.
  • Eve Air Mobility accomplished several milestones on our journey to shape the global Urban Air Mobility (UAM) ecosystem in 2023.
  • Our R&D costs are primarily driven by the MSA with Embraer that performs several developmental activities for Eve.
  • R&D associated with Eve's aircraft development and SG&A expenses were the main contributors to the higher cash consumption during the quarter.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Tuesday, March 5, 2024

The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.

Key Points: 
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.
  • BRAIN Biotech had already successfully used its protein engineering strategy in the development of a variety of protein and enzyme products in order to tailor them for industrial applications.
  • Pelzer cites powerful bioinformatics including the various AI approaches used by the experienced protein engineering experts at BRAIN Biotech as the basis for protein engineering, tailoring their approach to each specific inquiry.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner."